Optimal drug synergy in Antimicrobial Treatments

PLoS Computational Biology

Volumn 6, Issue 6, 2010, Pages 1-9

  Torella, Joseph Peter ^a,b   Chait, Remy ^a   Kishony, Roy ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY;

CLINICAL EFFICACY; DRUG COMBINATIONS; IN-VIVO; INFECTION DYNAMICS; INHIBITORY EFFECT; MULTIDRUG RESISTANCE; OPTIMAL TREATMENT; RESISTANT MUTANTS; SYNERGISTIC INTERACTION; WILD-TYPE CELLS;

DRUG INTERACTIONS;

ANTIBIOTIC AGENT; LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; INTERSPECIFIC COMPETITION; MATHEMATICAL MODEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; POPULATION DYNAMICS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE; ALGORITHM; ANIMAL; BIOLOGICAL MODEL; CLUSTER ANALYSIS; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; HUMAN; MICROBIOLOGY; MOUSE; PSEUDOMONAS INFECTION; TREATMENT OUTCOME;

ALGORITHMS; ANIMALS; ANTI-INFECTIVE AGENTS; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICE; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 77955480115     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000796     Document Type: Article

References (44)

1. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10: S122-S129.
2. Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW, eds. (2005) Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Philadelphia: Lippincott Williams & Wilkins.
3. Pillai SK, Moellering RC, Eliopoulos GM (2005) In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia: Lippincott Williams & Wilkins. Pp 365-440.
4. Rybak MJ, McGrath BJ (1996) Combination antimicrobial therapy for bacterial infections - Guidelines for the clinician. Drugs 52: 390-405.
5. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458-466.
6. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittel-Forschung-Drug Research 3: 285-290.
7. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41: 93-141.
8. Greco WR, Bravo G, Parsons JC (1995) The search for synergy - a critical review from a response-surface perspective. Pharmacol Rev 47: 331-385.
9. Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4: 71-78.
10. Michel JB, Yeh PJ, Chait R, Moellering RC, Kishony R (2008) Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci U S A 105: 14918-14923.
11. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R (2008) Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A 105: 13977-13981.
12. Klein M, Schorr SE (1953) The role of bacterial resistance in antibiotic synergism and antagonism. J Bacteriol 65: 454-465.
13. Chait R, Craney A, Kishony R (2007) Antibiotic interactions that select against resistance. Nature 446: 668-671.
14. Sanders CC, Sanders WE, Goering RV, Werner V (1984) Selection of multiple antibiotic-resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother 26: 797-801.
15. Mwangi MM, Wu SW, Zhou YJ, Sieradzki K, de Lencastre H, et al. (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104: 9451-9456.
16. Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB (1989) Crossresistance to fluoroquinolones in Multiple-Antibiotic-Resistant (MAR) Escherichia coli selected by tetracycline or chloramphenicol - decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 33: 1318-1325.
17. Normark BH, Normark S (2002) Evolution and spread of antibiotic resistance. J Intern Med 252: 91-106.
18. Larder BA, Kemp SD (1989) Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT). Science 246: 1155-1158.
19. Handel A, Regoes RR, Antia R (2006) The Role of Compensatory Mutations in the Emergence of Drug Resistance. PLoS Comput Biol 2.
20. Acar JF (2000) Antibiotic synergy and antagonism. Med Clin North Am 84: 1391-1406.
21. Jumbe N, Louie A, Leary R, Liu WG, Deziel MR, et al. (2003) Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112: 275-285.
22. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1-10; quiz 11-12.
23. Craig WA. Does the dose matter?; 2001 University of Chicago Press. pp S233-S237.
24. Eagle H, Fleischman R, Levy M (1953) "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med 248: 481-488.
25. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, et al. (2004) Pharmacodynamic functions: A multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 48: 3670-3676.
26. Smith VH, Holt RD (1996) Resource competition and within-host disease dynamics. Trends Ecol Evol 11: 386-389.
27. Lipsitch M, Dykes JK, Johnson SE, Ades EW, King J, et al. (2000) Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine 18: 2895-2901.
28. Dall'Antonia M, Coen PG, Wilks M, Whiley A, Millar M (2005) Competition between methicillin-sensitive and -resistant Staphylococcus aureus in the anterior nares. J Hosp Infect 61: 62-67.
29. Yeh P, Tschumi AI, Kishony R (2006) Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38: 489-494.
30. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7: 460-466.
31. Freter R, Brickner H, Botney M, Cleven D, Aranki A (1983) Mechanisms that control bacterial populations in continuous-flow culture models of mouse large intestinal flora. Infect Immun 39: 676-685.
32. Weinberg ED, Weinberg GA (1995) The role of iron in infection. Curr Opin Infect Dis 8: 164-169.
33. Nadell CD, Xavier JB, Levin SA, Foster KR (2008) The evolution of quorum sensing in bacterial biofilms. PLoS Biol 6: 171-179.
34. Zhang TC, Fu YC, Bishop PL (1995) Competition for substrate and space in biofilms. Water Environ Res 67: 992-1003.
35. Martinez JL, Baquero F (2000) Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 44: 1771-1777.
36. Tucker SP, Stiebel TR, Potts KE, Smidt ML, Bryant ML (1998) Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro. Antimicrob Agents Chemother 42: 478-480.
37. Meletiadis J, Stergiopoulou T, O'Shaughnessy EM, Peter J, Walsh TJ (2007) Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: Analysis by a new response surface model. Antimicrob Agents Chemother 51: 2053-2064.
38. Rand KH, Brown P (1995) Concentration-dependent synergy and antagonism between cefoperazone and imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 39: 1173-1177.
39. Lipsitch M, Levin BR (1997) The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 41: 363-373.
40. Roberts JA, Kruger P, Paterson DL, Lipman J (2008) Antibiotic resistance - What's dosing got to do with it? Crit Care Med 36: 2433-2440.
41. Knudsen JD, Odenholt I, Erlendsdottir H, Gottfredsson M, Cars O, et al. (2003) Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob Agents Chemother 47: 2499-2506.
42. Foo J, Michor F (2009) Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies. PLoS Comput Biol 5.
43. Grant AJ, Restif O, McKinley TJ, Sheppard M, Maskell DJ, et al. (2008) Modelling within-host spatiotemporal dynamics of invasive bacterial disease. PLoS Biol 6: 757-770.
44. Wodarz D (2006) Ecological and evolutionary principles in immunology. Ecol Lett 9: 694-705